# Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

> **NCT05488990** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lipidor AB** · enrollment: 24 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** AKVANO-Calcipotriol formulation 1
- **DRUG:** AKVANO-Calcipotriol formulation 2
- **DRUG:** AKVANO vehicle formulation 1
- **DRUG:** AKVANO vehicle formulation 2
- **DRUG:** Daivonex solution
- **DRUG:** Daivonex cream

## Key facts

- **NCT ID:** NCT05488990
- **Lead sponsor:** Lipidor AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-25
- **Primary completion:** 2013-06-17
- **Final completion:** 2013-06-17
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488990, "Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05488990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*